Skip to main content

Ingrezza Side Effects

Generic name: valbenazine

Medically reviewed by Philip Thornton, DipPharm. Last updated on May 25, 2023.

Note: This document contains side effect information about valbenazine. Some dosage forms listed on this page may not apply to the brand name Ingrezza.

Applies to valbenazine: oral capsule.

Warning

Oral route (Capsule)

Warning: Depression and Suicidal Ideation and Behavior in Patients with Huntington's DiseaseVMAT2 inhibitors, including valbenazine, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington's disease. Anyone considering the use of valbenazine must balance the risks of depression and suicidal ideation and behavior with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician.Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patient's with Huntington's disease.

Serious side effects of Ingrezza

Along with its needed effects, valbenazine (the active ingredient contained in Ingrezza) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking valbenazine:

Less common

Incidence not known

Other side effects of Ingrezza

Some side effects of valbenazine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to valbenazine: oral capsule.

General

-The most common adverse reaction (5% or more and twice the rate of placebo) was somnolence.

-A total of 3% of patients discontinued treatment because of adverse reactions.[Ref]

Nervous system

Very common (10% or more): Somnolence/fatigue/sedation (10.9%)

Common (1% to 10%): Anticholinergic effects (dry mouth, constipation, attention disturbance, blurred vision, urinary retention), balance disorders/fall/gait disturbance/dizziness, headache, akathisia/restlessness, drooling, dyskinesia,

non-akathisia extrapyramidal symptoms[Ref]

Gastrointestinal

Common (1% to 10%): Vomiting, nausea[Ref]

Hepatic

Common (1% to 10%): Increased alkaline phosphatase and bilirubin[Ref]

Metabolic

Common (1% to 10%): Increased blood glucose, increased weight, increased prolactin[Ref]

Musculoskeletal

Common (1% to 10%): Arthralgia[Ref]

Psychiatric

Common (1% to 10%): Anxiety, insomnia[Ref]

Respiratory

Common (1% to 10%): Respiratory infections[Ref]

Frequently asked questions

References

1. Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.